A STUDY ON CO-60 BASED HDR BRACHYTHERAPY OF UTERINE CERVIX CANCER PATIENTS

Ramesh Arya, Om Prakash Gurjar

Abstract


Background: HDR brachytherapy using Co-60 radioisotope is being used widely since past few years because of its few advantages over the Ir-192 radioisotope. The clinical outcome after all other benefits is most important, therefore it is important to analyse the Co-60 base HDR radiotherapy plans based on its dosimetric parameters. Materials and methods: Twenty patients diagnosed with uterine cervix cancer and treated with 50Gy/25# by external beam radiation therapy (EBRT) were included in this study. After insertion of three channel applicator CT simulation was done for all the patients. Clinical targets and organs at risk were delineated on the CT images and then HDR brachytherapy planning on CT images was done for 7Gy/# to deliver by Co-60 HDR brachytherapy unit. Dosimetric parameters were noted and analysed. All the patients were delivered three fractions on interval of one week between the fractions. Results:  High risk clinical target volume (HRCTV) was well covered with prescribed dose in all the plans with having doses to normal organs well within tolerance limit. Conclusion: Based on dosimetric parameters and their analysis for all the plans it can be concluded that Co-60 based HDR brachytherapy unit is a good choice for the boost treatment of uterine cervix cancer patients after EBRT.


Keywords


High dose rate brachytherapy, high risk clinical target volume, uterine cervix cancer

Full Text:

PDF

References


Schiffman M, Castle PE, Jeronim J, Rodrigue AC, Wacholde S.Human papillomavirus and cervical cancer. Lancet2007;370:890–907.

Sankaranarayanan R, Ferlay J. Worldwide burden ofgynecological cancer: the size of the problem. Best Pract ResClin Obstet Gynaecol 2006;20:207–25.

Gurjar OP, Batra M, Bagdare P, Kaushik S, Tyagi A, Bhandari V, Gupta KL, Naik A. A dosimetric study on Co-60 based high dose rate (HDR) brachytherapy in cervical cancer. Rep Pract Oncol Radiother 2016;21:201-6.

Banerjee R, Kamrava M. Brachytherapy in the treatment ofcervical cancer: a review. Int J Womens Health 2014;6:555–64.

Andrássy M, Niatsetsky Y, Pérez-Calatayud J. Co-60 versus Ir-192 in HDR brachytherapy: scientific and technological comparison. Rev Fis Med 2012;13:125–30.

Khan FM. The physics of radiation therapy. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2014.

Dimopoulos JC, Potter R, Lang S, et al. Dose–effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol 2009;93:311–5.

Georg P, Lang S, Dimopoulos JC, et al. Dose-volume histogram parameters and late side effects in magnetic resonance image-guided adaptive cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys 2011;79:356–62.

Bahadur YA, Constantinescu CT, Hassouna AH, EI-Sayed ME. Treatment planning for high dose rate brachytherapy of cervical cancer based on total dose constraints. Saudi Med J2011;32:495–503.

Palmer A, Hayman O, Muscat S. Treatment planning study ofthe 3D dosimetric differences between Co-60 and Ir-192sources in high dose rate (HDR) brachytherapy for cervixcancer. J Contemp Brachyther 2012;4:52–9.

Venselaar JL, van der Giessen PH, Dries WJ. Measurement and calculation of the dose at large distances from brachytherapy sources: Cs-137, Ir-192 and Co-60. Med Phys 1996;23:537–43.

Ntekim A, Adenipekun A, Akinlade B, Campbell O. High DoseRate Brachytherapy in the treatment of cervical cancer:preliminary experience with cobalt 60 radionuclide source – aprospective study. Clin Med Insights Oncol 2010;4:89–94.


Refbacks

  • There are currently no refbacks.